Jonestrading Reaffirms Hold Rating for DURECT (NASDAQ:DRRX)

Jonestrading reiterated their hold rating on shares of DURECT (NASDAQ:DRRX – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. Jonestrading currently has a $37.00 price objective on the specialty pharmaceutical company’s stock. A number of other research analysts also recently commented on DRRX. HC Wainwright downgraded DURECT from a […]

Leave a Reply

Your email address will not be published.

Previous post UK government and King Charles’ safety concerns highlight the importance of AI ethics
Next post RumbleON (NASDAQ:RMBL) & Lookers (OTCMKTS:LKKRF) Head-To-Head Comparison